about
Pathobiology of tobacco smoking and neurovascular disorders: untied strings and alternative productsMechanisms of RNA-induced toxicity in CAG repeat disordersPGC-1α, mitochondrial dysfunction, and Huntington's diseasePhysiological consequences of complex II inhibition for aging, disease, and the mKATP channelImpaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtinThe chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's diseaseMitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes.Inhibition of mitochondrial protein import by mutant huntingtinCabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicityBiology and genetics of prions causing neurodegenerationStriatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity.Indole and synthetic derivative activate chaperone expression to reduce polyQ aggregation in SCA17 neuronal cell and slice culture models.Oxidative stress, redox signalling and endothelial dysfunction in ageing-related neurodegenerative diseases: a role of NADPH oxidase 2.Influence of intensive multifunctional neurorehabilitation on neuronal oxidative damage in patients with Huntington's diseaseThe Immp2l mutation causes age-dependent degeneration of cerebellar granule neurons prevented by antioxidant treatment.Bidirectional transcription of trinucleotide repeats: roles for excision repair.Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtinEnhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review.Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease.HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response.Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies.Prospects for neuroprotective therapies in prodromal Huntington's disease.Sulfhydryl-mediated redox signaling in inflammation: role in neurodegenerative diseases.Main path and byways: non-vesicular glutamate release by system xc(-) as an important modifier of glutamatergic neurotransmission.SLC4A11 depletion impairs NRF2 mediated antioxidant signaling and increases reactive oxygen species in human corneal endothelial cells during oxidative stressDiscovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts.Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.hMTH1 expression protects mitochondria from Huntington's disease-like impairment.KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients.Metabolic and transcriptomic analysis of Huntington's disease model reveal changes in intracellular glucose levels and related genesUnhealthy smokers: scopes for prophylactic intervention and clinical treatment.Antioxidant effects of nerolidol in mice hippocampus after open field test.Ameliorating effect of Celastrus paniculatus standardized extract and its fractions on 3-nitropropionic acid induced neuronal damage in rats: possible antioxidant mechanism.Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo.A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.Deciphering the roles of trehalose and Hsp104 in the inhibition of aggregation of mutant huntingtin in a yeast model of Huntington's disease.The Emerging Field of Nutritional Mental Health
P2860
Q26777643-FB8743DF-3164-4D26-B47C-A8E3246EE992Q26860030-8F7E58C8-2C7D-46EC-803A-B127B9E06138Q27001671-F8CFEFBE-9DC8-4C48-AC62-394EA8DE138EQ27002338-F6F95617-D6C1-4779-9D2F-8D74AB9925F2Q27312215-1E075575-53B6-446D-A241-4D6CD955739FQ28072937-B7371EEE-08BA-4587-920A-55E67785FBDCQ28386769-66AE87C7-D7C4-4A34-A164-997EB99F3077Q28394803-84F67028-929F-4105-8796-8BA3AD327F03Q28539553-345160B0-AF3F-41C8-84BD-1D63EE513D4FQ33567229-A9D19746-10C5-4DB9-8E48-950053702ED0Q33831774-063C8B4D-9ED1-4063-84AE-985F06A4CA7FQ34386850-2A957AEC-219E-453C-8519-2AC6CCFBB5CDQ34570989-5CABE471-38E5-4A1A-B2DE-7B203A003502Q35904286-79BE0087-0AF0-4EC9-813E-DA47DE312910Q36475211-CD1AF7EC-B6BF-4BEA-A073-BE6749ACB398Q37038917-C6CAD49B-F2DD-4FCF-9D75-67364A6216FDQ37122279-FF6885AB-ACE6-4502-A365-690374385B14Q37153804-EA793446-E722-4C65-9816-3C0C85BCCA2AQ37368003-C917ED38-C811-4927-B61E-5ABCD4BED77FQ37575502-56A997CB-5046-47AB-8FD5-6057F6FF8FBBQ37607467-DF27E957-7F54-457D-9C7E-6BEE8FFDB82DQ37612752-D536C004-70D1-43D1-BC69-50C76CC87FACQ38167681-BBC557EE-52C5-411A-9218-4F1A7EE2FC44Q38191477-894B125E-3476-4934-91FA-F73A1CF95C5CQ38397575-0F5D3597-3850-4988-A3B1-6D7094EF78B2Q38580123-ABB1729F-D451-47DB-8DDC-657E4CA147B3Q38713044-21167148-6F74-4382-8273-50DFAE4AA976Q38792714-115F770E-7DF0-449B-9734-CF27EF3A9C25Q39199926-1DA3412D-47AA-4F9F-ACFC-41E1125A3E41Q39279550-C8612282-7ED4-4454-8DA4-61800B77914FQ39375357-AAB9390A-0EAF-4311-A2BD-E84111E150B9Q41563536-D478EC6D-4B29-4F2F-B8AE-20293BF01BDEQ42376534-74E00E30-60A6-4A7A-9896-5C3161D9318DQ44726809-20B4DEDC-25FD-46E3-88A2-5F7341750729Q45300396-DEC5FAC9-B71A-45B9-BCBE-F4483509C376Q45302345-350BA913-5637-44CA-9ABB-01EBBF699A25Q45305356-2AC96D4E-98BE-45F0-AB17-AA8D447812BEQ52721984-4A6A084E-A8F5-497C-8DF6-2DFBA9E90318Q54576258-9E01FEFF-40B3-447C-8CEF-E2D4BDE73607Q56675883-7E807F69-1704-4E22-8C0F-21288689ECB7
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Antioxidants in Huntington's disease.
@en
Antioxidants in Huntington's disease.
@nl
type
label
Antioxidants in Huntington's disease.
@en
Antioxidants in Huntington's disease.
@nl
prefLabel
Antioxidants in Huntington's disease.
@en
Antioxidants in Huntington's disease.
@nl
P2860
P1476
Antioxidants in Huntington's disease.
@en
P2093
Ashu Johri
M Flint Beal
P2860
P304
P356
10.1016/J.BBADIS.2011.11.014
P407
P577
2011-11-23T00:00:00Z